JAK Safety Update Dr. Jonathan Kay offers his perspectives on abstracts POS0150, POS0151, and POS0157 presented at the

Social Author Image
https://pbs.twimg.com/profile_images/1915149062988271616/2m4z_QPt_normal.jpg
Tweet Author
RheumNow
Social Author Name
Dr. John Cush
Tweet Content
JAK Safety Update Dr. Jonathan Kay offers his perspectives on abstracts POS0150, POS0151, and POS0157 presented at the 2025 EULAR meeting in Barcelona, Spain. https://t.co/F8WzGohCj8 https://t.co/FguBLrmPzZ
Links
JAK Safety Update | RheumNow https://buff.ly/4FB5GsB

Harnessing AI in axSpA: The Promise of Digital Therapeutics with Axia The management of axial spondyloarthritis (axSpA

Social Author Image
https://pbs.twimg.com/profile_images/1915149062988271616/2m4z_QPt_normal.jpg
Tweet Author
RheumNow
Social Author Name
Dr. John Cush
Tweet Content
Harnessing AI in axSpA: The Promise of Digital Therapeutics with Axia The management of axial spondyloarthritis (axSpA) continues to evolve with the integration of artificial intelligence (AI) and digital health technologies. Traditionally, treatment has centered around https://t.co/5CCpZqkm7K

Pregnancy outcomes in autoinflammatory disease To address this, a French multi-centre prospective pregnancy observatio

Social Author Image
https://pbs.twimg.com/profile_images/1915149062988271616/2m4z_QPt_normal.jpg
Tweet Author
RheumNow
Social Author Name
Dr. John Cush
Tweet Content
Pregnancy outcomes in autoinflammatory disease To address this, a French multi-centre prospective pregnancy observational cohort was set up, to analyse disease activity, treatment, pregnancy outcomes, delivery, and neonatal health. The work – presented at the 2025 annual https://t.co/oQ7A2bnDmO

From Domains to Decisions: Personalizing PsA Care with Data At EULAR 2025, Dr. Laura Coates (Oxford) took the plenary

Social Author Image
https://pbs.twimg.com/profile_images/1915149062988271616/2m4z_QPt_normal.jpg
Tweet Author
RheumNow
Social Author Name
Dr. John Cush
Tweet Content
From Domains to Decisions: Personalizing PsA Care with Data At EULAR 2025, Dr. Laura Coates (Oxford) took the plenary stage to reframe how we think about treating psoriatic arthritis. The message was clear: in 2025, PsA treatment is no longer about following a linear algorithm; https://t.co/tzgE7U4eSj

New ideas in gout management Gout flares are associated with cardiovascular events. Treating gout to target serum urat

Social Author Image
https://pbs.twimg.com/profile_images/1915149062988271616/2m4z_QPt_normal.jpg
Tweet Author
RheumNow
Social Author Name
Dr. John Cush
Tweet Content
New ideas in gout management Gout flares are associated with cardiovascular events. Treating gout to target serum urate level prevents flares, but whether such treatment can also prevent cardiovascular events is unknown. https://t.co/C8G39JzP9Y https://t.co/NAClL0JLGX
Links
New ideas in gout management | RheumNow https://buff.ly/SwsTd2L

Reviewing Three Osteoarthritis Studies Dr. Janet Pope discusses abstracts POS0492, abstract POS0565, and abstract POS0

Social Author Image
https://pbs.twimg.com/profile_images/1915149062988271616/2m4z_QPt_normal.jpg
Tweet Author
RheumNow
Social Author Name
Dr. John Cush
Tweet Content
Reviewing Three Osteoarthritis Studies Dr. Janet Pope discusses abstracts POS0492, abstract POS0565, and abstract POS0612 presented at the EULAR 2025 meeting in Barcelona, Spain. https://t.co/0qub4ITnxa https://t.co/uguzPSnvCR
Links
Reviewing Three Osteoarthritis Studies | RheumNow https://buff.ly/3qhHAH9

Which CAR T Cell is Mighty? Dr. Yuz Yusof talks with Dr. Chris Wincup about CAR T data being presented at the EULAR 20

Social Author Image
https://pbs.twimg.com/profile_images/1915149062988271616/2m4z_QPt_normal.jpg
Tweet Author
RheumNow
Social Author Name
Dr. John Cush
Tweet Content
Which CAR T Cell is Mighty? Dr. Yuz Yusof talks with Dr. Chris Wincup about CAR T data being presented at the EULAR 2025 meeting in Barcelona, Spain. https://t.co/MkRoqlvdub https://t.co/R0dtllmo7Q
Links
Which CAR T Cell is Mighty? | RheumNow https://buff.ly/BFnpo4e
19 June 2025
What would it take for JAKs to ROCK the boat?
JAK inhibitors have taken a beating over the last three years. The excitement and potential has been tempered by mounting cardiovascular safety concerns, but specifically in at-risk patients, compared to TNF inhibitors. So it is an intriguing idea to pair JAK inhibitors with something that might have a cardioprotective effect. It is therefore worth excitement that we have a therapeutic option to follow which does just that. At EULAR 2025, we have seen phase 2 results for CPL’116, and a simultaneous publication in The Lancet Rheumatology.

All Rheumatoid Arthritis is Not the Same

Subscribe to
How well do you know this week's rheumatology news?
Take the rheumIQ quiz
Take the RheumIQ Quiz

×